Shopping Cart
PRP in Otology: What Studies Show About Eardrum Healing, Sudden Hearing Loss and Tinnitus
Short answer: Platelet-rich plasma (PRP) is being investigated in several areas of otology. The comparatively strongest clinical evidence currently concerns PRP as an adjunct in the repair of tympanic membrane perforations. There are positive clinical signals in sudden sensorineural hearing loss, but the evidence remains limited. For tinnitus, the data are insufficient to classify PRP as an established treatment.
Important in sudden hearing loss: Newly occurring sudden hearing loss should be assessed promptly by an ENT specialist. Current PRP evidence does not replace diagnostic work-up or guideline-based treatment decisions.
What is relatively well studied?PRP as an adjunct to myringoplasty or tympanoplasty in selected tympanic membrane perforations.
What remains unclear?Optimal PRP composition, dose, application schedule and long-term effect.
What has not been proven?A general efficacy of PRP for tinnitus or sensorineural hearing loss.
PRP in otology: evidence at a glance
Otologic PRP applications should not be treated as a single indication. Evidence for tympanic membrane repair, acute sensorineural hearing loss and tinnitus differs substantially in quality and volume.
Evidence: moderate
Tympanic membrane perforation / myringoplasty / tympanoplasty
Several randomized studies and recent meta-analyses suggest that platelet concentrates – and PRP in PRP-specific analyses – may improve closure or graft-uptake rates when used as an adjunct to surgical repair. PRP is being studied as an addition, not as a replacement for surgery.
Evidence: low
Sudden sensorineural hearing loss (SSNHL)
Small prospective, retrospective and comparative studies report improved hearing thresholds after intratympanic PRP in some patients. Large, methodologically robust randomized trials with adequate follow-up are still lacking.
Evidence: very low
Tinnitus
Tinnitus has often been recorded only as a symptom accompanying SSNHL. A small quasi-experimental comparative study published in 2026 found no significant difference in median Tinnitus Handicap Inventory after four weeks between PRP and intratympanic steroid.
Evidence: insufficient
Ménière disease, presbycusis, acoustic trauma
Exploratory clinical reports exist, but without suitable control groups they do not support a reliable treatment recommendation.
How to read this: “Moderate evidence” does not mean PRP is established standard care. It means that tympanic membrane repair is supported by substantially more and methodologically stronger clinical data than intratympanic use for inner-ear disorders.
Interactive evidence explorer
Select an indication to see how strong the clinical conclusion is at present.
Eardrum
Multiple randomized studies and meta-analyses. PRP is studied as an adjunct to defined repair procedures.
Comparatively strongest evidenceSSNHL
Positive signals from small clinical studies, but heterogeneous protocols and limited follow-up.
ExperimentalTinnitus
Very small evidence base. A direct 2026 comparison found no significant difference in median THI after four weeks.
No robust efficacy proofOther indications
Ménière disease, presbycusis and acoustic trauma remain exploratory research fields.
Insufficient evidenceWhat is PRP – and why is one PRP not necessarily the same as another?
Platelet-rich plasma is an autologous plasma fraction prepared from blood and containing an increased platelet concentration. Platelets carry and release numerous bioactive mediators, including growth factors and cytokines involved in wound healing, angiogenesis and tissue remodelling.
A key issue when reading clinical studies is that there is no universally standardized PRP product. Blood volume, anticoagulant, centrifugation method, relative centrifugal force (RCF), number of spins, platelet concentration, leukocyte and erythrocyte content, activation, final volume and application schedule can differ substantially.
What changes a PRP preparation?
Blood & anticoagulant
Starting volume and anticoagulant influence the preparation.
Centrifugation
RCF, run time, rotor and number of spins affect cell distribution.
Cell profile
Platelet, leukocyte and erythrocyte content may vary markedly.
Application
Activation, final volume, dose, number and timing of applications are not standardized.
Two studies can both use the term “PRP” while applying biologically different preparations. This complicates direct comparison and transfer of one study protocol to another system.
Tympanic membrane perforation: currently the strongest clinical evidence
The best studied otologic PRP application currently concerns not tinnitus or sudden hearing loss, but support of tympanic membrane healing during myringoplasty or tympanoplasty.
A 2025 systematic review and meta-analysis of platelet concentrates included 13 randomized studies with 1,179 patients with chronic otitis media. Adding PRP or PRF was associated with a higher graft-uptake rate at six months (OR 2.45; 95% CI 1.34–4.47). The air-bone gap also improved slightly more on average.
PRP-specific meta-analyses published in 2026 further support this signal. For fat-graft myringoplasty, one analysis included five studies with 522 participants and found a higher closure rate with PRP (OR 3.13; 95% CI 1.88–5.20). Another meta-analysis of type I cartilage tympanoplasty also reported higher success rates when PRP was added.
Important: These findings concern PRP as an adjunct to defined surgical procedures in selected patient groups. They do not show that every tympanic membrane perforation can be treated with PRP alone.
PRP for sudden sensorineural hearing loss
In idiopathic sudden sensorineural hearing loss (SSNHL), PRP is mainly being studied via intratympanic administration into the middle ear. The biological rationale is to position mediators near the round-window membrane and therefore close to an entry route to the inner ear. It remains insufficiently established whether and to what extent PRP components reach the human inner ear and produce clinically relevant effects.
A 2024 prospective study included 56 patients with unilateral SSNHL who had responded inadequately to previous conventional treatment. After two intratympanic PRP applications, mean hearing gain was 11.99 dB. The study had no control group.
A 2024 comparative study of 100 patients compared intratympanic PRP with intratympanic steroids and reported larger hearing gains in the PRP group. However, the design was not a robust randomized, blinded efficacy trial.
A retrospective comparative study published in August 2026 included 50 patients. At one month, mean hearing gain was reported as 30.4 dB with PRP versus 19.8 dB with dexamethasone. The study was small, retrospective and had short follow-up. It strengthens the clinical signal but does not change the experimental status of PRP.
Guideline status
The AAO-HNS guideline for sudden sensorineural hearing loss lists corticosteroids as an option for initial treatment within two weeks and recommends intratympanic steroids as salvage therapy for incomplete recovery two to six weeks after symptom onset. PRP is not listed as a standard treatment.
Clinical relevance: PRP should not be presented in SSNHL as a substitute for time-sensitive diagnostic assessment or guideline-based treatment.
PRP for tinnitus: early data, but no robust proof of efficacy
Evidence for tinnitus is considerably weaker. In older PRP studies, tinnitus was often captured only as a symptom accompanying SSNHL. In the prospective 56-patient SSNHL study, eight of 17 patients with tinnitus reported subjective improvement; this was a secondary outcome without a tinnitus-specific control group.
A quasi-experimental study published in 2026 compared intratympanic PRP with intratympanic steroid in 50 patients. After four weeks, the median Tinnitus Handicap Inventory (THI) was 8 in the PRP group and 9 in the steroid group; the direct difference was not statistically significant (p=0.546).
The fair conclusion in 2026: There are early clinical signals for PRP in tinnitus, but not enough robust evidence to call PRP an effective or established tinnitus treatment. PRP is also not part of established standard care in the German S3 guideline for chronic tinnitus.
Ménière disease, presbycusis and acoustic trauma: exploratory evidence
A 2026 publication examined 150 patients with different forms of sensorineural hearing loss, including idiopathic SSNHL, acoustic trauma, presbycusis and Ménière disease. All patients received four intratympanic PRP applications and hearing improvements were reported in several groups.
Because there was no adequate untreated or standard-therapy control group for the individual diagnoses, it is not possible to determine how much of the change was caused by PRP. Evidence therefore remains exploratory.
Animal models and laboratory studies provide hypotheses about anti-inflammatory, angiogenic, cytoprotective or neurotrophic effects. They do not prove clinically relevant regeneration of damaged human hair cells or auditory nerves.
Interactive research pipeline
Open each step to see what must happen before biological plausibility becomes reliable clinical evidence.
1 · Mechanism
Growth factors, cytokines and cellular responses provide a biological hypothesis. That is not yet evidence of clinical benefit.
2 · Preclinical models
Animal and laboratory studies can examine plausibility and safety questions but cannot be transferred directly to patients.
3 · Early clinical studies
Small cohorts can show signals but are vulnerable to selection effects, natural history and protocol differences.
4 · Controlled trials
Randomization, comparison groups, standardized outcomes and adequate follow-up are essential.
5 · Guidelines & practice
Only a consistent body of evidence supports reliable placement in guidelines and clinical standards.
Safety, standardization and unanswered questions
Published small otologic studies have mainly reported transient local effects such as dizziness or discomfort at the injection site; serious PRP-related events have been uncommon. The number of treated patients is nevertheless too small to reliably exclude rare complications.
| Open question | Why it matters |
|---|---|
| Which PRP composition? | Platelet concentration, leukocyte content and activation differ between protocols. |
| What dose and volume? | There is no generally validated otologic dosing scheme. |
| How many applications? | Studies use different numbers of sessions and intervals. |
| What timing? | SSNHL is time-dependent; early and late treatment cannot simply be compared. |
| Which patient group? | SSNHL, presbycusis, Ménière disease and acoustic trauma have different pathophysiologies. |
| How long does any effect last? | Many studies have short follow-up periods. |
A 2026 expert consensus on PRP in regenerative medicine identifies variability in PRP production and activation, small sample sizes and methodological differences as central problems.
For healthcare professionals: A publication about “PRP” does not automatically establish that a specific tube or preparation system is suitable for a particular otologic application. Intended purpose, instructions for use, regulatory status and the documented clinical process remain decisive.
What can reasonably be said in 2026?
- Tympanic membrane healing: PRP is much better studied as an adjunct to myringoplasty/tympanoplasty than intratympanic PRP for inner-ear disorders.
- SSNHL: Several small studies show a positive signal, but evidence is not sufficient for an established standard treatment.
- Tinnitus: Data are very limited; a general claim of efficacy would not be justified.
- Ménière disease, presbycusis, acoustic trauma: exploratory data only, without a robust treatment recommendation.
- Standardization: Studies are difficult to compare without precise reporting of the PRP product and protocol.
Frequently asked questions about PRP in otology
Is PRP an established treatment for tinnitus?
No. As of 31 August 2026, there is no sufficiently robust evidence or established guideline status for PRP as a tinnitus treatment.
Can PRP be used for sudden hearing loss?
PRP is being clinically studied in SSNHL, particularly intratympanically. It is not an established standard treatment and should not delay prompt ENT assessment.
Where is PRP best studied in otology?
The comparatively strongest clinical evidence concerns PRP or platelet concentrates as an adjunct during surgical repair of tympanic membrane perforations.
Does PRP regenerate damaged inner-ear hair cells?
This has not been demonstrated in humans. Preclinical models provide biological hypotheses but no clinical proof of hair-cell regeneration.
Why are PRP studies hard to compare?
Preparation, platelet concentration, leukocyte content, activation, volume, centrifugation parameters and application schedules can differ substantially.
Selected references and guidelines
- Bayounos S, et al. Clinical Outcomes of Platelet-Rich Plasma in Otology: A Systematic Review of Tympanoplasty, Myringoplasty, and Hearing Loss Management. Cureus. 2026;18(2):e104045. Source
- Alahmadi RA, et al. Platelet Concentrates Impact on Myringoplasty Outcomes in Chronic Otitis Media Patients: Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2025;172(1):25-35. Source
- Kang YJ, Stybayeva G, Hwang SH. Efficacy and Safety of Fat Graft Myringoplasty Combined With Platelet-Rich Plasma for Managing Chronic Tympanic Membrane Perforations: A Systematic Review and Meta-Analysis. Clin Exp Otorhinolaryngol. 2026;19(1):70-78. Source
- Kang YJ, Stybayeva G, Hwang SH. The effectiveness and safety of combining platelet-rich plasma with cartilage tympanoplasty type 1 to treat tympanic membrane perforations: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2026;283(5):2795-2802. Source
- Sharma S, et al. Intratympanic Platelet-Rich Plasma Therapy for Sudden Sensorineural Hearing Loss: A Preliminary Prospective Study. 2024. Source
- Shawky M. Management of Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) Intratympanic Platelet-Rich Plasma (PRP) Versus Intratympanic Steroid Injections: A Cross-Sectional Study. Otolaryngol Pol. 2024;78(3):1-6. Source
- Gupta K, et al. Emerging biological therapy vs. conventional steroid treatment in unilateral sudden sensorineural hearing loss (SSNHL): a comparative study. Egypt J Otolaryngol. 2026;42:209. Source
- Asghar AM. Effects of intra-tympanic platelet-rich plasma and conventional method in patients with tinnitus: A comparative study. Mediterr J Med Med Sci. 2026;2(3):56-61. Source
- Shawky MA, Shawky AA, Zakaria NZ. Role of platelet-rich plasma in management of sensorineural hearing loss diseases. Vestn Otorinolaringol. 2026;91(1):4-10. Source
- Chandrasekhar SS, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update). Otolaryngol Head Neck Surg. 2019;161(1 Suppl):S1-S45. Source
- Dillard LK, et al. Interventions for sudden sensorineural hearing loss: a systematic review and quality assessment of clinical practice guidelines. Int J Audiol. 2026;65(6):639-651. Source
- AWMF. S3-Leitlinie Chronischer Tinnitus, Registernummer 017-064, Version 4.1. Source
- Danese M, et al. Expert Consensus on the use of autologous platelet-rich plasma in the context of regenerative medicine: moving forward to good clinical practice. Ann Ist Super Sanità. 2026;62(1):16-31. Source
PRP preparation: keep technical workflow separate from the treatment claim
For professional PRP workflows, healthcare professionals can find tubes, centrifuges and accessories at prpmed.de. Product availability does not mean that a product is intended or clinically suitable for a particular otologic indication. Manufacturer information and instructions for use remain decisive.
View PRP range
